Kang WZ, Shi JM, Wang BZ, Xiong JP, Shao XX, Hu HT, Jin J, Tian YT. Adjuvant chemoradiotherapy vs adjuvant chemotherapy in locally advanced Siewert type II/III adenocarcinoma of gastroesophageal junction after D2/R0 resection. World J Gastrointest Oncol 2022; 14(8): 1540-1551 [PMID: 36160743 DOI: 10.4251/wjgo.v14.i8.1540]
Corresponding Author of This Article
Yan-Tao Tian, PhD, Professor, Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. tianyantao@cicams.ac.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Aug 15, 2022; 14(8): 1540-1551 Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1540
Adjuvant chemoradiotherapy vs adjuvant chemotherapy in locally advanced Siewert type II/III adenocarcinoma of gastroesophageal junction after D2/R0 resection
Wen-Zhe Kang, Jian-Ping Xiong, Xin-Xin Shao, Hai-Tao Hu, Yan-Tao Tian, Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Jin-Ming Shi, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Bing-Zhi Wang, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Jing Jin, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangdong Province, China
Author contributions: Tian YT and Jin J designed the research; Kang WZ, Shi JM, Wang BZ, Xiong JP and Shao XX analyzed the data and wrote the paper; Hu HT collected the patient’s clinical data; Kang WZ and Shi JM contributed equally to this work.
Supported byNational Natural Science Foundation of China, No. 82072734.
Institutional review board statement: The study was reviewed and approved by the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Institutional Review Board, No. 17-156/1412.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Dataset available from the first author at kwz@whu.edu.cn.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan-Tao Tian, PhD, Professor, Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. tianyantao@cicams.ac.cn
Received: May 6, 2022 Peer-review started: May 6, 2022 First decision: June 12, 2022 Revised: June 19, 2022 Accepted: July 22, 2022 Article in press: July 22, 2022 Published online: August 15, 2022 Processing time: 96 Days and 2.6 Hours
ARTICLE HIGHLIGHTS
Research background
The role of adjuvant chemoradiotherapy (CRT) in adenocarcinoma of gastroesophageal junction (AGE) is unclear.
Research motivation
Radiotherapy may reduce the local recurrence rate and prolong survival time for locally advanced Siewert II/III type adenocarcinoma of AGE.
Research objectives
To evaluate the effect of adjuvant CRT vs adjuvant chemotherapy (CT) on overall survival (OS), relapse-free survival (RFS), and recurrence pattern in locally advanced Siewert II/III type adenocarcinoma of AGE patients undergoing D2/R0 resection.
Research methods
We compared the OS, RFS, and recurrence modes between the adjuvant CRT and adjuvant CT groups.
Research results
Adjuvant CRT improves the 5-year survival rate of adenocarcinoma of AGE, especially Siewert type III adenocarcinoma of AGE, and reduces local and regional recurrence rates.
Research conclusions
Adjuvant CRT may be appropriate for adenocarcinoma of AGE, especially for Siewert type III adenocarcinoma of AGE.
Research perspectives
Multicenter prospective clinical trials should be conducted to investigate the significance of adjuvant CRT in adenocarcinoma of AGE.
